By Ian Walker

AstraZeneca raised its full-year guidance for core earnings per share and total revenue excluding Covid-19 medicines despite a lower third-quarter profit that missed forecasts.

The Anglo-Swedish pharmaceutical giant said Thursday that it expects core earnings per share to increase by a low double-digit percentage compared with previous guidance of a high single-digit to low double-digit percentage increase.

Total revenue excluding Covid-19 medicines is now expected to increase by a low-teens percentage at constant exchange rates compared with previous expectations of low double-digit percentage growth.

Write to Ian Walker at ian.walker@wsj.com

(END) Dow Jones Newswires

November 09, 2023 02:35 ET (07:35 GMT)

Copyright (c) 2023 Dow Jones & Company, Inc.
AstraZeneca (NASDAQ:AZN)
Historical Stock Chart
Von Jun 2024 bis Jul 2024 Click Here for more AstraZeneca Charts.
AstraZeneca (NASDAQ:AZN)
Historical Stock Chart
Von Jul 2023 bis Jul 2024 Click Here for more AstraZeneca Charts.